Literature DB >> 19387079

Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.

Vassiliki Poulaki1, Constantine S Mitsiades, Vassiliki Kotoula, Joseph Negri, Ciaran McMullan, Joan W Miller, Paul A Marks, Nicholas Mitsiades.   

Abstract

PURPOSE: To characterize the molecular sequelae induced in retinoblastoma (Rb) cells by histone deacetylase inhibitors (HDACIs). Hydroxamic acid-based HDACIs such as vorinostat (suberoylanilide hydroxamic acid) induce the differentiation and apoptosis of transformed cells. Vorinostat has demonstrated significant anticancer activity against hematologic and solid tumors at doses well tolerated by patients and has been approved for the treatment of patients with cutaneous T-cell lymphoma.
METHODS: The authors evaluated the effects of the HDACIs vorinostat and m-carboxycinnamic acid bis-hydroxamide on the Rb cell lines Y79 and WERI-Rb1 with the use of the MTT assay, BrdU incorporation assay, flow cytometry, immunoblotting, gene-expression profiling, quantitative RT-PCR, and NF-kappaB DNA-binding assay.
RESULTS: Both HDACIs were effective against both Rb cell lines, inducing growth arrest and apoptosis in vitro. Vorinostat increased p53 expression and activated caspases -8, -9 and -3, whereas caspase inhibition abrogated vorinostat-induced apoptosis. Vorinostat downregulated baseline NF-kappaB activity and potentiated the activity of the DNA-damaging chemotherapeutic doxorubicin. Gene expression profiling and qRT-PCR demonstrated that vorinostat modulated the mRNA levels of genes important for signal transduction, cell cycle, cellular metabolism, stress response, apoptosis, extracellular matrix synthesis, and cell differentiation. Notably, several transcripts involved in the ephrin and Notch signaling pathways were upregulated.
CONCLUSIONS: HDACIs, such as vorinostat, induce caspase-dependent apoptosis in Rb cells, downregulate baseline NF-kappaB activity, and potentiate the effectiveness of conventional chemotherapy. The finding that vorinostat augments the effectiveness of doxorubicin provides a rationale for future clinical studies looking at the use of vorinostat in combination with conventional chemotherapy in Rb.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19387079     DOI: 10.1167/iovs.09-3517

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy.

Authors:  Nicholas Mitsiades; Sue Anne Chew; Bin He; Aline I Riechardt; Theano Karadedou; Vassiliki Kotoula; Vassiliki Poulaki
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-09-14       Impact factor: 4.799

2.  Forkhead box N4 (Foxn4) activates Dll4-Notch signaling to suppress photoreceptor cell fates of early retinal progenitors.

Authors:  Huijun Luo; Kangxin Jin; Zhenhui Xie; Feng Qiu; Shengguo Li; Min Zou; Li Cai; Katsuto Hozumi; David T Shima; Mengqing Xiang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-08       Impact factor: 11.205

Review 3.  The paradigm of drug resistance in cancer: an epigenetic perspective.

Authors:  Swagata Adhikari; Apoorva Bhattacharya; Santanu Adhikary; Vipin Singh; Shrikanth S Gadad; Siddhartha Roy; Chandrima Das
Journal:  Biosci Rep       Date:  2022-04-29       Impact factor: 3.976

4.  Transposable element dysregulation in systemic lupus erythematosus and regulation by histone conformation and Hsp90.

Authors:  Maurer Kelly; Shi Lihua; Zhang Zhe; Song Li; Paucar Yoselin; Petri Michelle; E Sullivan Kathleen
Journal:  Clin Immunol       Date:  2018-08-24       Impact factor: 3.969

Review 5.  Histone Deacetylases Inhibitors in the Treatment of Retinal Degenerative Diseases: Overview and Perspectives.

Authors:  Hua Zhang; Xufeng Dai; Yan Qi; Ying He; Wei Du; Ji-Jing Pang
Journal:  J Ophthalmol       Date:  2015-06-02       Impact factor: 1.909

Review 6.  Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives.

Authors:  Robert Jenke; Nina Reßing; Finn K Hansen; Achim Aigner; Thomas Büch
Journal:  Cancers (Basel)       Date:  2021-02-05       Impact factor: 6.639

7.  UHRF1 downmodulation enhances antitumor effects of histone deacetylase inhibitors in retinoblastoma by augmenting oxidative stress-mediated apoptosis.

Authors:  Jong Kyong Kim; Guangyan Kan; Yu Mao; Zhixuan Wu; Xionghong Tan; Heng He; Chunsik Lee
Journal:  Mol Oncol       Date:  2019-12-13       Impact factor: 6.603

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.